| 2.32 -0.1 (-4.13%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.04 | 1-year : | 5.2 |
| Resists | First : | 3.46 | Second : | 4.46 |
| Pivot price | 2.53  |
|||
| Supports | First : | 1.85 | Second : | 1.53 |
| MAs | MA(5) : | 2.33 |
MA(20) : | 2.47 |
| MA(100) : | 1.93 |
MA(250) : | 1.51 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 20.1 |
D(3) : | 19.5 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 4.46 | Low : | 0.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALLO ] has closed above bottom band by 26.7%. Bollinger Bands are 55.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.43 - 2.44 | 2.44 - 2.45 |
| Low: | 2.2 - 2.22 | 2.22 - 2.22 |
| Close: | 2.3 - 2.32 | 2.32 - 2.34 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Tue, 21 Apr 2026
Allogene (NASDAQ: ALLO) RSU vests 9,586 shares; Form 144 filed 04/21/2026 - Stock Titan
Tue, 21 Apr 2026
Allogene Therapeutics (ALLO) Expands Groundbreaking Study in Sou - GuruFocus
Tue, 21 Apr 2026
Allogene expands lymphoma trial to South Korea, Australia - Investing.com
Tue, 21 Apr 2026
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - Yahoo Finance
Mon, 20 Apr 2026
Allogene (NASDAQ: ALLO) proxy urges approval to raise authorized shares to 800M - Stock Titan
Mon, 20 Apr 2026
Allogene Therapeutics Showcases Momentum with Clinical and - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 331 (M) |
| Shares Float | 204 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 45.4 (%) |
| Shares Short | 32,060 (K) |
| Shares Short P.Month | 23,930 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.9 % |
| Return on Equity (ttm) | -53.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.46 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -149 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -2.67 |
| PEG Ratio | 0 |
| Price to Book value | 1.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|